Oral Minoxidil for Hair Loss in Childhood Cancer Survivors

Overseen By Danielle Friedman, MD, MS

Age: < 65

Sex: Any

Trial Phase: Phase 2

Sponsor: Memorial Sloan Kettering Cancer Center

Must not be taking: Alopecia therapies, Anticancer therapies

Disqualifiers: Scalp disorders, Hypotension, Cardiovascular disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 8 months

60 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if taking minoxidil by mouth (an oral medication) can improve hair loss in children and young adults who have completed cancer treatment. Researchers seek to assess the treatment's safety, the occurrence of only mild side effects, and participants' adherence to their medication schedule. The trial also examines the treatment's impact on participants' quality of life. Individuals who underwent cancer treatments before age 17, have experienced hair loss for over six months post-treatment, and are now aged 6 to 18 might be suitable for this study. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot use other therapies for hair loss while participating.

Is there any evidence suggesting that oral minoxidil is likely to be safe for humans?

Research has shown that taking minoxidil by mouth is generally safe for treating hair loss. Studies with adults have found that both the pill form and the topical form (applied to the skin) of minoxidil work well and are safe. These studies reported no significant side effects for users.

For children and young adults who have lost hair due to cancer treatment, taking minoxidil by mouth has also proven safe. Researchers noted no major side effects, making it a promising option for managing hair loss in this group.

Overall, evidence suggests that oral minoxidil is well-tolerated and can be considered a safe treatment option for hair loss. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for hair loss?

Researchers are excited about oral minoxidil for treating hair loss in childhood cancer survivors because it's a new approach compared to traditional topical solutions. Unlike current treatments like topical minoxidil or wigs, this oral form allows the medication to work systemically, potentially offering a more convenient and consistent way to promote hair growth. Additionally, oral minoxidil may provide an alternative for those who have not responded well to topical treatments. This new delivery method could make a significant difference in the quality of life for survivors looking for effective hair restoration options.

What evidence suggests that oral minoxidil might be an effective treatment for hair loss in childhood cancer survivors?

Research has shown that oral minoxidil can help with hair loss. A review of studies found that people with hair loss might benefit from oral minoxidil, especially at higher doses. In another study, over 20% of cancer survivors experienced new hair growth and thicker hair with oral minoxidil. Additionally, researchers have found oral minoxidil to be safe for treating hair loss, with no major side effects. In this trial, participants will receive either oral minoxidil or a placebo followed by oral minoxidil. These findings suggest that oral minoxidil could improve hair loss caused by cancer treatments. ^{1 2 3 6 7}

Who Is on the Research Team?

Alina K Markova, MD, PhD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

This trial is for children and young adults aged 6-18 who are cancer survivors with hair loss related to past chemotherapy or radiation. They must have finished their cancer treatment at least a year ago, not be on other alopecia treatments, and can't have low blood pressure or certain heart conditions.

Inclusion Criteria

I finished my cancer treatment (chemotherapy or radiation) over a year ago.

I have had hair loss for over 6 months due to past cancer treatment.

I was diagnosed with cancer before turning 17.

Exclusion Criteria

I am not currently on any cancer treatments like chemotherapy or immunotherapy.

I have a history of fainting or low blood pressure.

My blood pressure is below 90/50 mmHg.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive oral minoxidil or placebo for hair loss treatment

8 months

Regular visits for monitoring and assessment

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Oral Minoxidil
• Placebo

Trial Overview

The study is testing if oral Minoxidil helps improve hair growth in young cancer survivors compared to a placebo. It will also assess the drug's safety, adherence to dosing schedules by participants, and its impact on their quality of life.

How Is the Trial Designed?

Group I: Oral Minoxidil Experimental Treatment 1 Intervention

Patients receive oral minoxidil at a dose of 0.01 (\<40kg) and 0.02 (≥40kg) mg/kg/day for 8 months

Group II: Placebo followed by oral Minoxidil Active Control 2 Interventions

Patient receive placebo for 4 months followed by oral minoxidil for 4 months

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Published Research Related to This Trial

In a study involving 22 women undergoing chemotherapy, topical minoxidil significantly reduced the time from maximum hair loss to the first signs of hair regrowth, shortening the baldness period by an average of 50.2 days.

The use of minoxidil was found to be safe, with no significant side effects reported, making it a promising option for managing chemotherapy-induced hair loss.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A randomized trial of minoxidil in chemotherapy-induced alopecia. Duvic, M., Lemak, NA., Valero, V., et al.[2013]

Topical minoxidil (TMX) is commonly used for treating hair loss in children, but it is not FDA-approved for those under 18, and there are no established guidelines for its use in pediatric patients.

Oral minoxidil (OMX) has been used off-label in very low doses for hair loss in children, but dermatologists should be cautious of potential systemic absorption risks, as there is no consensus on the appropriate dosing or minimum age for treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Topical and oral minoxidil for hair disorders in pediatric patients: What do we know so far? Lemes, LR., Melo, DF., de Oliveira, DS., et al.[2021]

In a study involving 48 female cancer patients undergoing doxorubicin-based chemotherapy, the 2% topical solution of minoxidil was found to be non-toxic, showing no adverse effects.

However, minoxidil did not effectively prevent severe hair loss (alopecia) during chemotherapy, as 88% of patients in the minoxidil group and 92% in the placebo group experienced severe hair loss.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia. Rodriguez, R., Machiavelli, M., Leone, B., et al.[2020]

In a pilot study involving 10 women undergoing chemotherapy for gynecologic cancers, 2% topical Minoxidil was found to be non-toxic and did not cause any side effects, such as skin changes or hypotension.

Despite its known efficacy in treating male pattern baldness, Minoxidil showed no significant benefit in preventing hair loss during chemotherapy, as 5 out of 6 evaluable patients experienced severe hair loss within four weeks.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. Granai, CO., Frederickson, H., Gajewski, W., et al.[2020]

In a study of 20 pediatric patients aged 2 months to 13 years who received high doses of oral minoxidil, 65% experienced hypertrichosis (excessive hair growth), typically starting around 24 days after treatment began.

While 15% of the patients showed systemic effects from the medication, none experienced severe disorders, indicating that while side effects can occur, they may not be life-threatening.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Systemic Minoxidil Accidental Exposure in a Paediatric Population: A Case Series Study of Cutaneous and Systemic Side Effects. Sánchez-Díaz, M., López-Delgado, D., Montero-Vílchez, T., et al.[2021]

Minoxidil is an FDA-approved topical treatment for hair loss in both men and women, available in 2% and 5% formulations, and is generally considered safe but should be used with caution due to potential side effects.

A case of non-arteritic anterior ischemic optic neuropathy was reported in a patient using 5% minoxidil, which resolved after stopping the treatment, highlighting the need for awareness of rare but serious side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Could Topical Minoxidil Cause Non-Arteritic Anterior Ischemic Optic Neuropathy? Aktas, H., Alan, S., Türkoglu, EB., et al.[2020]

In a study comparing hair loss after different treatment approaches for medulloblastoma, 70% of patients receiving chemotherapy followed by craniospinal radiotherapy (C-CSRT) experienced hair loss in the cranial field, compared to only 30% in those who had surgery followed by craniospinal radiotherapy (CSRT).

Age was found to significantly influence the extent of hair loss, highlighting that persistent hair loss is a notable late effect of treatment that can impact patients' quality of life and should be considered in future clinical trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of permanent hair loss in children with standard risk PNETS of the posterior fossa following radiotherapy alone or chemotherapy and radiotherapy after surgical resection. Rogers, S., Donachie, P., Sugden, E., et al.[2011]

A review of 63 pediatric patients (ages 0-12) treated with low-dose oral minoxidil (LDOM) or sublingual minoxidil (SM) showed that these treatments were generally well-tolerated, with mild hypertrichosis being the most common side effect.

There is currently a lack of recommended treatment guidelines for the use of minoxidil in children, highlighting the need for further large-scale studies to assess its efficacy and optimal dosage for treating alopecia in this age group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review. John, JM., Sinclair, RD.[2023]

Persistent or permanent hair loss can occur in breast cancer patients after treatment with taxane chemotherapy and endocrine therapy, as demonstrated in a case study of a 59-year-old woman.

Topical minoxidil therapy showed significant clinical improvement for the patient's alopecia, suggesting it may be a reasonable treatment option for hair loss in breast cancer patients following chemotherapy or hormonal therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Persistent Alopecia in a Breast Cancer Patient Following Taxane Chemotherapy and Adjuvant Endocrine Therapy: Case Report and Review of Post-treatment Hair Loss in Oncology Patients with Breast Cancer. Werbel, T., Cohen, PR.[2020]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT05778825

A Study of Oral Minoxidil to Treat Hair Loss in Children ...

See Delay Results Type in the Results Data ... A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors.

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12188453/

Efficacy and safety of oral minoxidil in the treatment of alopecia

This systematic review and meta-analysis indicate that individuals with hair loss may derive benefits from oral minoxidil, particularly at doses exceeding 1 mg.

3.

nature.com

nature.com/articles/s41598-024-53054-8

Topical minoxidil and dietary supplement for the treatment ...

Among the 70 patients evaluated, 61 (87.1%) experienced clinical improvement. Patients in the groups with superior treatment outcomes received a ...

4.

withpower.com

withpower.com/trial/phase-2-alopecia-2-2023-0b315

Oral Minoxidil for Hair Loss in Childhood Cancer Survivors

The use of minoxidil was found to be safe, with no significant side effects reported, making it a promising option for managing chemotherapy-induced hair loss.

5.

ascopost.com

ascopost.com/issues/december-10-2022/how-low-dose-oral-minoxidil-is-providing-hope-for-patients-with-later-stage-alopecia/

How Low-Dose Oral Minoxidil Is Providing Hope for ...

Your study found more than a 20% clinical benefit in restoring hair growth and density in both the frontal and occipital scalp areas of cancer survivors with ...

6.

careacross.com

careacross.com/clinical-trials/trial/NCT05778825

A Study of Oral Minoxidil to Treat Hair Loss in Children ...

Summary: This study will test whether minoxidil taken by mouth (oral minoxidil) can improve hair loss caused by cancer treatment in children and young adults.

7.

cancer.gov

cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-02581

Minoxidil for Alopecia in Young Cancer Survivors

Giving minoxidil may increase hair growth and may improve quality of life in pediatric and young adult cancer survivors. Eligibility Criteria ...